Insiders · APUS

APUS insider transactions

Apimeds Pharmaceuticals US Inc. (APUS) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

Recent Form 3, 4, and 5 filings for APUS

• 155d
  Amendment: SEC Form 4 filed by Large owner Inscobee Inc.

  4/A - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 163d
  SEC Form 4 filed by Director Weintraub Bennett

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 163d
  SEC Form 4 filed by Director Yoon Hankil

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 163d
  SEC Form 4 filed by Director Koo Jakap

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 163d
  SEC Form 4 filed by Director O'Donnell Carol A

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 163d
  SEC Form 4 filed by Director Kogan Elona

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 184d
  SEC Form 4 filed by Director Kogan Elona

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 187d
  SEC Form 4 filed by Director O'Donnell Carol A

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 190d
  SEC Form 4 filed by Director Koo Jakap

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 190d
  SEC Form 4 filed by Director Weintraub Bennett

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 190d
  SEC Form 4 filed by Chairman and CMO Kim Christopher

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 190d
  SEC Form 4 filed by Director Yoon Hankil

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 190d
  SEC Form 4 filed by Chief Executive Officer Emerson Erik C.

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 319d
  Amendment: Large owner Inscobee Inc. converted options into 115,131 shares, increasing direct ownership by 6% to 2,099,747 units (SEC Form 4)

  4/A - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 319d
  Amendment: New insider Inscobee Inc. claimed ownership of 5,619,232 shares (SEC Form 3)

  3/A - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 340d
  SEC Form 4 filed by Director Kogan Elona

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 340d
  SEC Form 4 filed by Director Yoon Hankil

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 340d
  SEC Form 4 filed by Director O'Donnell Carol A

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 340d
  Chairman and CMO Kim Christopher was granted 250,000 shares, increasing direct ownership by 909% to 277,500 units (SEC Form 4)

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 341d
  Chief Executive Officer Emerson Erik C. was granted 750,000 shares (SEC Form 4)

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 341d
  SEC Form 4 filed by Director Weintraub Bennett

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 341d
  SEC Form 4 filed by Director Koo Jakap

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 345d
  Chairman and CMO Kim Christopher bought $50,359 worth of shares (27,500 units at $1.83) (SEC Form 4)

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 346d
  Director Koo Jakap bought $56,715 worth of shares (28,500 units at $1.99), increasing direct ownership by 5% to 643,885 units (SEC Form 4)

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 346d
  Large owner Inscobee Inc. bought $2,000,000 worth of shares (500,000 units at $4.00) and converted options into 297,133 shares, increasing direct ownership by 37% to 2,028,657 units (SEC Form 4)

  4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
• 346d
  Amendment: New insider Inscobee Inc. claimed ownership of 5,619,232 shares (SEC Form 3)

  3/A - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)